Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20
iPS Cell Differentiation01:22

iPS Cell Differentiation

3.2K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
3.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Long-Term Disease Stability Assessed by the Expanded Disability Status Scale in Patients Treated with Cladribine Tablets 3.5 mg/kg for Relapsing Multiple Sclerosis: An Exploratory Post Hoc Analysis of the CLARITY and CLARITY Extension Studies.

Advances in therapy·2021
Same author

COVID-19 vaccines and multiple sclerosis disease-modifying therapies.

Multiple sclerosis and related disorders·2021
Same author

Treatment-emergent adverse events occurring early in the treatment course of cladribine tablets in two phase 3 trials in multiple sclerosis.

Multiple sclerosis journal - experimental, translational and clinical·2021
Same author

Evaluation of remote assessments for multiple sclerosis in an in-home setting.

Multiple sclerosis and related disorders·2021
Same author

Update on the management of multiple sclerosis during the COVID-19 pandemic and post pandemic: An international consensus statement.

Journal of neuroimmunology·2021
Same author

Probing the association between Multiple Sclerosis and Epstein Barr Virus from a therapeutic perspective.

Multiple sclerosis and related disorders·2021

Related Experiment Video

Updated: Feb 18, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K

Personalized medicine in multiple sclerosis.

Gavin Giovannoni1

  • 1Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London E1 2AT, UK.

Neurodegenerative Disease Management
|November 17, 2017
PubMed
Summary

Personalized medicine for multiple sclerosis (MS) needs better biomarkers and understanding of disease stages. Current approaches lag behind the need for tailored patient treatments, highlighting a therapeutic window challenge.

Keywords:
disease definitionmultiple sclerosispersonalized medicinetaxonomy

More Related Videos

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K

Related Experiment Videos

Last Updated: Feb 18, 2026

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
05:55

Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research

Published on: December 1, 2023

1.4K
Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

12.9K
Comprehensive Autopsy Program for Individuals with Multiple Sclerosis
09:41

Comprehensive Autopsy Program for Individuals with Multiple Sclerosis

Published on: July 19, 2019

12.1K

Area of Science:

  • Neuroimmunology
  • Neurology
  • Personalized Medicine

Background:

  • Current multiple sclerosis (MS) treatment lacks personalization due to insufficient biomarkers and understanding of its pathogenesis.
  • The concept of precision medicine is not yet fully implementable for MS.
  • A patient-focused approach is crucial for personalized medicine in MS.

Purpose of the Study:

  • To explore the need for a personalized medicine framework in multiple sclerosis (MS).
  • To address key questions regarding MS taxonomy, disease onset, and progression.
  • To highlight the implications of a disease spectrum and therapeutic lag on treatment strategies.

Main Methods:

  • Review of current therapeutic approaches in MS.
  • Analysis of emerging evidence on MS pathogenesis and disease progression.
  • Discussion of the challenges in defining MS taxonomy and therapeutic windows.

Main Results:

  • Evidence suggests MS represents a spectrum of disease rather than distinct entities.
  • A significant therapeutic lag exists, with benefits from disease-modifying therapies observed years later.
  • Accurate staging of MS and monitoring of inflammatory lesions are critical for personalized treatment.

Conclusions:

  • A personalized medicine approach, moving beyond precision medicine, is essential for effective MS management.
  • Further research into MS pathogenesis and biomarkers is required to refine disease taxonomy and optimize treatment timing.
  • Understanding the disease spectrum and therapeutic lag is key to improving patient outcomes in MS.